Therapeutics in Huntington's Disease. - Wikidata - wikimedia - TriplyDB

Therapeutics in Huntington's Disease.

Therapeutics in Huntington's Disease.

http://www.wikidata.org/entity/Q39252195

about

Treating psychosis in movement disorder patients: a review.Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches?Progress in developing transgenic monkey model for Huntington's disease.

P2860

Q38213306-86F46E64-350C-43B0-9FA6-C4487496C91E Q38244078-789B9F76-969D-44A5-A4AA-FCAA1520E6B5 Q47974512-10A277CC-7FCF-4E96-9B79-FCEEC3B4EA22

P2860

Therapeutics in Huntington's Disease.

http://www.wikidata.org/entity/Q39252195

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Therapeutics in Huntington's Disease.

@en

Therapeutics in Huntington's Disease.

@nl

type

label

Therapeutics in Huntington's Disease.

@en

Therapeutics in Huntington's Disease.

@nl

prefLabel

Therapeutics in Huntington's Disease.

@en

Therapeutics in Huntington's Disease.

@nl

P1433

Q39252195-F702BA6B-6FC4-4BAA-86A1-F2B65743AE02

P1476

Q39252195-3BC3724A-FB08-44B6-BACA-EA9B1BF09184

P2093

Q39252195-E0FFAB9F-CB4F-421A-B068-F67EBB8CB107

Q39252195-F6E4B374-E096-4CB5-B47D-49FA5040EE42

P2860

Q39252195-0A2FB3D0-67A0-4358-A351-1B836501B587

Q39252195-154765DD-365C-4E5A-AEC5-B09524188D30

Q39252195-1861A6B1-8106-41B5-9BFC-1709A7A5AAE5

Q39252195-19A5B97F-9307-4969-BA09-3DDDFF3CA710

Q39252195-1A8B2A67-EA87-40CC-85E5-93EB0D320406

Q39252195-26CFE756-592B-4B65-8BB0-23C33B33DF4B

Q39252195-3079A97A-4249-4E1A-ADB9-7FC70DD4F616

Q39252195-34091696-E740-4169-B9BF-C21017269B2C

Q39252195-4037D6EF-4104-45AE-AA94-8C7E2063912D

Q39252195-4A61B260-9035-40D4-833D-2269477914B2

P2888

Q39252195-F43A71BD-F44F-480C-8F6F-1EA8F0C77565

P31

Q39252195-C7D34EF4-941E-4343-BD50-00A3042EF741

P356

Q39252195-5DE791C5-AF23-4DE3-A5F7-ABD4E9ABEB13

P577

Q39252195-E74A846B-CB7A-44B3-884A-710169FF58E3

P698

Q39252195-27D3A9B8-5851-4758-AFD1-479C367E82D6

P921

Q39252195-D74D29AB-7F14-4FEE-8596-8416FC5B26A4

P356

S11940-012-0165-X

P1433

Current treatment options in neurology

P1476

Therapeutics in Huntington's Disease.

@en

P2093

Annie Killoran

http://www.w3.org/2001/XMLSchema#string

Kevin M Biglan

http://www.w3.org/2001/XMLSchema#string

P2860

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

Huntington's disease

Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series.

Huntington's disease: from molecular pathogenesis to clinical treatment.

Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.

Gene therapy in mouse models of huntington disease.

Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease.

Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease.

Symptomatic treatment of Huntington disease

The current clinical management of Huntington's disease.

P2888

s11940-012-0165-x

P31

scholarly article

P356

10.1007/S11940-012-0165-X

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22314929

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease